Table 1.
Characteristics of included studies
| First author/year | Location | Type of malignancy included | Duration of study | Total no. of pts with HM | Total no. of pts with HM hospitalized | Median age of pts with HM, y | Female pts with HM, N (%) | Died, N (%) | No. of pts who had not yet recovered/ unknown status at end of study |
|---|---|---|---|---|---|---|---|---|---|
| Adult studies | |||||||||
| Aries20/2020* | Europe | All | 2 mo | 35 | 24 | 69 | 12 (34) | 14 (40) | 0 |
| Biernat21/2020 | Europe | All | 1 mo | 10 | 10 | 58 | 8 (80) | 7 (70) | 0 |
| Booth22/2020* | Europe | All | 2 mo | 66 | 66 | 73 | 25 (38) | 34 (52) | 4 |
| Cook23/2020* | Europe | Myeloma | 15 wk | 75 | 72 | 73 | 30 (40) | 41 (55) | NR |
| Dufour24/2020* | Europe | Myeloma | NR | 20 | 18 | 68 | 8 (40) | 7 (35) | NR |
| Engelhardt25/2020 | Europe | Myeloma | 3 mo | 21 | 17 | 59 | 4 (19) | 0 (0) | NR |
| Fattizzo26/2020* | Europe | All | 6 wk | 16 | 13 | 77 | 6 (38) | 5 (31) | NR |
| Ferrara27/2020 | Europe | AML | 1 mo | 10 | 10 | 60 | 5 (50) | 5 (50) | 1 |
| Fox28/2020* | Europe | All | 1 mo | 54 | 51 | 63 | 18 (33) | 19 (35) | 1 |
| He29/2020 | Asia | All | 3 wk | 13 | 13 | 35 | 6 (46) | 8 (62) | 0 |
| Hultcrantz30/2020 | North America | Myeloma | 7 wk | 100 | 74 | 68 | 42 (42) | 18 (18) | NR |
| Infante31/2020 | Europe | All | 1 mo | 41 | 29 | 76 | 19 (47) | 15 (37) | NR |
| Kuderer32/2020 | Multicenter | All | 1 mo | 204† | 104 | NR | NR | 24 (14) | NR |
| Lattenist33/2020* | Europe | All | 2 mo | 12 | 12 | 74 | 3 (25) | 6 (50) | NR |
| Lee34/2020 | Europe | All | 6 wk | 169 | NR | NR | NR | 60 (36) | 0 |
| Malard35/2020 | Europe | All | 1 mo | 25 | 25 | 72 | 8 (32) | 10 (40) | NR |
| Martín-Moro36/2020* | Europe | All | 5 wk | 34 | 34 | 73 | 15 (44) | 11 (32) | 5 |
| Mato37/2020 | Multicenter | CLL | 2.5 mo | 198 | 178 | 71 | 73 (37) | 66 (33) | 49 |
| Mehta38/2020* | North America | All | 3 wk | 54 | 54 | NR | NR | 20 (37) | NR |
| Mei39/2020 | Asia | All | Unclear | 13 | 13 | NR | NR | 6 (46) | NR |
| Passamonti40/2020 | Europe | All | 12 wk | 536 | 451 | 68 | 196 (37) | 198 (37) | 11 |
| Patell41/2020* | North America | All | 2 mo | 19 | 19 | NR | NR | 13 (68) | 4 |
| Razanamahery42/2020* | Europe | All | 8 wk | 20 | 20 | 69 | 7 (35) | 6 (30) | NR |
| Rugge43/2020 | Europe | All | 5 wk | 81 | 48 | NR | NR | 13 (16) | NR |
| Russell44/2020 | Europe | All | 10 wk | 28 | NR | NR | NR | 7 (25) | NR |
| Sanchez-Pina45/2020 | Europe | All | 1 mo | 39 | 34 | 65 | 16 (41) | 14 (40) | 19 |
| Scarfò46/2020* | Europe | CLL | 10 wk | 190 | 169 | 72 | 64 (34) | 56 (29) | 38 |
| Shah47/2020 | Europe | All | 8 wk | 80 | 80 | 73 | 28 (35) | 28 (35) | 5 |
| Tian48/2020 | Asia | All | 9 wk | 12 | 12 | NR | 5 (42) | 5 (42) | NR |
| Varma49/2020 | North America | All | NR | 34 | 25 | 57 | 12 (35) | 7 (21) | NR |
| Wang50/2020 | North America | Myeloma | 2 mo | 58 | 36 | 67 | 28 (48) | 14 (24) | 0 |
| Yang51/2020 | Asia | All | 2 mo | 22 | 22 | 55 | 7 (32) | 9 (41) | 0 |
| Yigenoglu52/2020 | Asia | All | 15 wk | 740 | 452 | 56 | 343 (46) | 102 (14) | NR |
| ASH registry53/2020* | Multicenter | All | Ongoing (3 mo at time of data extraction) | 264‡ | 176 | NR | 106 (40) | 74 (30) | 16 |
| Pediatric studies | |||||||||
| Bisogno54/2020 | Europe | All | 2 mo | 20 | NR | NR | NR | 0 (0) | 0 |
| de Rojas55/2020 | Europe | All | NR | 11 | NR | 11 | 1 (9) | 0 (0) | NR |
| Faura56/2020 | Europe | All | 3 mo | 41 | NR | NR | NR | 2 (5) | NR |
| Ferrari57/2020 | Europe | All | 8 wk | 12 | NR | NR | NR | 0 (0) | NR |
| ASH registry53/2020* | Multicenter | All | Ongoing (3 mo at time of data extraction) | 18 | NR | NR | NR | 2 (11) | 2 |
AML, acute myeloid leukemia; ASH, American Society of Hematology; CLL, chronic lymphocytic leukemia; HM, hematologic malignancy; NR, not reported; pts, patients; UK, United Kingdom.
*
Authors who provided extra information via e-mail communication.
†
Outcome data only available on 167 patients.
‡
Outcome data only available on 248 patients.